MEND Adopted by Geisinger to Enhance Patient Care

Press Release (ePRNews.com) - NEW YORK - Oct 08, 2019 - MEND, a clinical nutrition company located in BioLabs@NYULangone in New York City, announced today that it has been added to Geisinger’s formulary. The product, MEND Joint Replacement (www.mendjoint.com), crosses a very high bar for scientific efficacy and operational review by a leader in value-based care and will be integrated into standard of care for all joint replacement patients.

Geisinger, an integrated health care system based in Danville, Pennsylvania, serves over 1.5 million patients and is considered a national leader and innovator in value-based care — a new model of bundled payments that incentivizes hospitals to improve patient outcomes.

“MEND aligns with our philosophy of providing our patients comprehensive multimodal care to deliver the best possible results,” says said Michael Suk, M.D., J.D., chair of the Geisinger Department of Orthopaedic Surgery. “For our total joint population, this new nutritional therapy will help to enhance outcomes.”

MEND, which has been implemented by several leading hospitals in orthopedics, is supported by a number of randomized placebo-controlled clinical trials that show enhanced outcomes in joint replacement populations. When taken pre- and post-surgery, patients taking the formula will preserve more muscle volume and strength, have faster recovery and return to function and have lower postoperative inflammation and complications.

“We’re thrilled that such an influential hospital system has decided to make MEND standard of care for their joint replacement patients,” says MEND’s Founder and CEO Eziah Syed. “There is billions of dollars of cost in healthcare related to malnutrition and associated complications. Our safe and effective solution addresses some key challenges for the joint replacement population, improves outcomes and patient experience and reduces healthcare costs. We are excited to work with Geisinger to give their patients the best in care.”

About MEND

Founded and headquartered in New York City, MEND is a life sciences company with a mission to help people heal and live their healthiest. The company is currently researching and developing targeted clinical nutrition products to enhance patient outcomes, from injury and surgery, to aging and physical performance. MEND has been adopted by numerous hospitals, professional sports teams across all major leagues and the elite forces of the US Military. For more information, visit mend.me or connect with us on Facebook, Instagram, LinkedIn and Twitter. Contact Jasmine for press inquiries: jasmine@mend.me.

About Geisinger

One of the nation’s most innovative health services organizations, Geisinger serves more than 1.5 million patients in Pennsylvania and New Jersey. The system includes 13 hospital campuses, a nearly 600,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. A physician-led organization, with approximately 32,000 employees and more than 1,800 employed physicians, Geisinger leverages an estimated $12.7 billion positive annual impact on the Pennsylvania and New Jersey economies. Repeatedly recognized nationally for integration, quality and service, Geisinger has a long-standing commitment to patient care, medical education, research and community service. For more information, visit geisinger.org or connect with us on Facebook, Instagram, LinkedIn and Twitter.

Source : MEND
SHARE :  

You may also like this  

CATEGORIES : Healthcare

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login

DISCLAIMER

If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.